EUDA Health Holdings Ltd

EUDA Health Holdings Limited has terminated its At The Market (ATM) Offering Agreement with Chardan Capital Markets LLC, which allowed for the sale of up to $10,000,000 in ordinary shares. The company sent a termination notice on June 5, 2026, with the termination becoming effective on July 22, 2026. The ATM Offering has been suspended as of June 10, 2026, and no shares were sold under the agreement. EUDA will file a prospectus supplement to reduce the offering to zero.

EUDA Health Holdings Limited announced the expansion of its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask. This new beauty product, developed by Chemokine Pte Ltd, utilizes iPSC-derived skin stem cell secretome technology for skin hydration, brightening, and recovery. EUDA, which holds exclusive global distributorship rights for Helixé products, intends to use its established networks in Malaysia and China to drive sales in the growing Asia-Pacific facial mask market, estimated at $7.95 billion in 2026 and projected to reach $9.08 billion by 2031.

EUDA Health Holdings Limited announced the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, expanding its Helixé product line. Developed by Chemokine Pte Ltd, for which EUDA holds exclusive global distributorship, the mask utilizes iPSC-derived skin stem cell secretome technology. EUDA aims to capitalize on the growing global face mask market, estimated at $7.95 billion in 2026 and projected to reach $9.08 billion by 2031, by leveraging its established distribution networks in Malaysia and China to drive sales across the Asia-Pacific region.

EUDA Health Holdings Ltd announced it has regained compliance with Nasdaq's Minimum Market Value of Listed Securities (MVLS) requirement. The company initially received a notice on April 23, 2026, for failing to maintain the $35 million MVLS threshold. However, by May 28, 2026, Nasdaq confirmed that EUDA Health's MVLS had been $35 million or greater for ten consecutive business days, from May 13 to May 27, 2026, thus resolving the non-compliance issue.

EUDA Health Holdings Ltd announced that its partner, Shenzhen Inno Immune Co., Ltd., received official approval under the 2025 Shenzhen Key Industry R&D Program. This government initiative is expected to provide funding of up to approximately US$434,688 to Shenzhen Inno for its "Key Technology Development of TCR-T Therapy for Solid Tumors" project, scheduled from January 1, 2026, to December 31, 2028. EUDA holds non-exclusive distribution rights to market and sell selected immunotherapies from Shenzhen Inno to customers in Malaysia. This development aligns with EUDA's strategy to expand access to advanced treatment modalities.

EUDA Health Holdings Ltd received a written notice from Nasdaq on April 23, 2026, indicating non-compliance with the Minimum Market Value of Listed Securities (MVLS) rule. The company failed to maintain an MVLS of $35 million over the last 32 consecutive business days. EUDA has 180 calendar days, until October 20, 2026, to regain compliance by having its MVLS close at $35 million or more for a minimum of ten consecutive business days. Failure to do so could result in delisting from Nasdaq.